glp 1 agonist moa Frontiers Mechanisms of GLP-1 Receptor Agonist-Induced
Description
Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Wilding JPH, Leiter LA, Bhatt DL, et al
Cirrhotic progression was documented in 3% and 4% of tirzepatide and placebo cohorts, respectively
PMID: 41563749
Studies suggest that tirzepatide can lead to greater weight loss than Ozempic , with some patients losing more than 20% of their body weight
Federation WO (2022) London: World Obesity Federation
